----
Current ValuationThe current P/E ratio is -45.27, below the reasonable range, cheaper than 95.91% of the time in the past 3 years, and the industry ranks 68/84, the industry Median 19.01.
-45.27xP/E
¥58.10Stock price
¥-1.28Earnings per share
-45.27xP/E
Stock price¥58.10Earnings per share¥-1.28
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -25.96x
- Typical range
- -36.69x–-16.24x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 19.01x
023466992
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 19.01x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
688180SHJunshi Biosciences | -70.78x | 81.90% | ¥31.20B |
300122SZZHIFEI-BIOL | -2.21x | 91.91% | ¥31.10B |
603392SHWantai Biological | -66.05x | 22.02% | ¥30.09B |
688192SHDizal Pharmaceutical | -45.27x | 255.85% | ¥27.03B |
300676SZBGI Genomics | -30.76x | 118.23% | ¥16.77B |
688520SHSinocelltech | -16.89x | 171.21% | ¥15.14B |
688319SHOlymvax Biopharmaceuticals | -445.78x | 227.87% | ¥10.61B |
688806SHTrinomab Pharmaceutical | -22.74x | -- | ¥10.24B |
688765SHHEALTHGEN BIOTECH | -70.61x | -- | ¥10.00B |
688062SHMabwell | -9.31x | 37.63% | ¥9.78B |
300204SZStaidson BioPharm | -104.00x | -- | ¥9.35B |
688137SHNovoprotein | -107.46x | -- | ¥8.89B |
688443SHGenrix Bio | -15.20x | 32.19% | ¥8.55B |
688382SHInventisBio | -23.55x | 5.45% | ¥7.88B |
002030SZDAJY | -10.12x | -- | ¥7.52B |
688177SHBIO-THERA | -16.30x | 2.47% | ¥7.19B |
300294SZBOYA BIOLOGY | -115.94x | 281.82% | ¥7.13B |
688759SHBeBetter Med | -34.04x | 12.50% | ¥6.73B |
688276SHBCHT | -27.74x | 66.67% | ¥6.69B |
688488SHAidea Pharma | -920.18x | -- | ¥5.33B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
